"We really try to limit the amount of tissue we resect and what we do in patients who've had radiation," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses patient selection for ...

18F-DCFPyL PET/CT shows high detection rates in biochemically recurrent prostate cancer with low PSA levels, suggesting its utility in early metastatic disease identification. The study included 129 ...

"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD. The Society of Benign Prostatic Disease ...

“We took the urine from those patients, and we tested to see if we can predict their gemcitabine metabolism capability. We were able to predict it pretty accurately,” says Laura Bukavina, MD, MPH. In ...

“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the ...

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment ...

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment ...

In this video, Kate H. Gessner, MD, PhD, discusses the mechanisms of immunotherapy failure in renal cell carcinoma, which was discussed during a case-based session at the 2025 American Society of ...

The CLEAR trial demonstrated lenvatinib plus pembrolizumab's superior efficacy over sunitinib in advanced renal cell carcinoma, with robust response rates and significant tumor shrinkage. Sustained ...

Piflufolastat F18 scans led to treatment changes in 45% of newly diagnosed and 74% of recurrent prostate cancer cases. Clinicians reported increased confidence in treatment decisions, with 96% ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared to sunitinib in advanced RCC patients. The combination therapy showed a median PFS of 16.4 months versus 8.3 months for ...

Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by ...